Navigation Links
Rx for Africa, Inc. Signs Letter of Intent for Strategic Alliance with Rusan Pharma, Ltd. of India
Date:6/8/2009

NEW YORK, June 8 /PRNewswire-FirstCall/ -- Rx for Africa, Inc. announced today the signing of a letter of intent for a strategic alliance with Rusan Pharma, Ltd., of Mumbai, India. The alliance commences immediately, with Rusan providing Rx for Africa Inc. the tuberculosis (TB) drug, "RUCOX-4" (four drug combination) as per the recommended dosage form of the World Health Organization (WHO), which is also approved by the Ethiopian Ministry of Health and already marketed in some CIS & African countries. Per capita the highest number of deaths and the highest mortality from TB in the world are in Sub-Saharan Africa. "Tuberculosis is a huge problem in our region," said Dr. Mulugetta Bezzabeh, CEO of Rx for Africa, "and RUCOX-4 is an important addition to our product line. We expect significant revenue and profit to be derived from marketing it."

In addition, the agreement also maps out a strategy in which Rx Africa (Ethiopia) PLC will market Rusan Pharma's 202 drugs in Ethiopia, and other sub-Saharan African countries. Importantly, Rusan will assist Rx in developing anti-malarials and HIV medications for these markets, and will assist us to start manufacturing their whole list of drugs in our Ethiopian facilities. Dr. Navin Saxena, Chairman of Rusan Pharma, Ltd. commented, "Rusan is pleased to enter into strategic alliance with Rx for Africa. Ethiopia is a big market with significant potential for growth in the area of Tuberculosis, HIV AIDS & Malaria products. Rusan has the capability to develop various drug delivery systems besides the conventional dosage forms and will use its expertise to bring these to the market in short time."

Rx for Africa will hold a conference call on Thursday, June 11th at 4:30pm EDT with Dr. Mulugetta Bezzabeh, Chairman and CEO, presenting. Dial-in instructions for the call will be available on our website by 1pm today at http://rxforafrica.com

About Rx for Africa, Inc.

Rx for Africa, Inc., a public New Jersey corporation formed in 2007, invests in companies manufacturing generic pharmaceuticals in Sub-Saharan Africa. Rx Africa (Ethiopia) P.L.C. is a wholly-owned operating subsidiary, with a campus just outside Addis Ababa, Ethiopia: factory, R&D center and office facilities, currently producing six generic pharmaceutical products. The company sells 100% of its current production through distributors. Shares of Rx for Africa, Inc. common stock are traded under the symbol RXAF.PK on the Pink Sheets. For more information, visit Rx for Africa's website: http://rxforafrica.com.

About Rusan Pharma, Ltd.

Established in 1994, Rusan specializes in the areas of pain management, substitution treatment, opioid withdrawal, anti- tuberculosis, psychiatric drugs and anti-infectives. Its facilities include an ultra-modern formulations unit approved by UK MHRA, South Africa MCC, Zimbabwe MCAZ, WHO-GMP and Sudan MOH. Rusan markets its products in Europe, the Middle East, The CIS, South East Asia and African countries and has obtained the Certificate of Suitability (COS) of Buprenorphine Hydrochloride from the European Directorate of Quality Medicine (EDQM).

For more information, visit Rusan Pharma Ltd.'s website: http://www.rusanpharma.com.

Forward Looking Statements

This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties, including the failure to complete the development of new or enhanced products, the Company's future capital needs, the lack of market demand for any new or enhanced products the Company may develop, any actions by the Company's partners or others that may be adverse to the Company, the success of competitive products, other economic factors affecting the Company and its markets, seasonal changes, and other risks detailed from time to time in the Company's filings with the U.S. Securities and Exchange Commission. The actual results may differ materially from those contained in this press release. The Company disclaims any obligation to update any statements in this press release.


'/>"/>
SOURCE Rx for Africa, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Former Executive at Genzyme Corp. and Osiris Therapeutics, Inc. to Head Business Advisory Board at Rx for Africa, Inc.
2. Rx for Africa, Inc. to Benefit from New Ethiopian Government Policy on Pharma Industry
3. AIDS Remains Leading Cause of Death in Africa, According to UN
4. LSUHSC researchers first to document early signs for diabetes in kids as young as 7
5. Overweight male teens with normal blood pressures showing signs of heart damage
6. Recognizing signs and symptoms of acute HF
7. Nuvilex Signs Agreement with Jayhur Enterprises to Distribute Infinitink - the Worlds First Permanent, But Easier to Remove Tattoo Ink - in Australia and New Zealand
8. Oklahoma Passes Comprehensive Tort Reform: Governor Brad Henry Signs Reform Legislation
9. SETO Holdings, Inc. Signs Agreement to Acquire Advanced Hearing Centers, Inc. and Will Dispose of All Existing Business; New Management to be Installed
10. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
11. Martek Signs Sole-Source ARA Supply Agreement with Lactalis Nutrition Sante
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2017)... Louisiana (PRWEB) , ... April 29, 2017 , ... ... Brookshire’s Grocery Company to the list of fine retailers selling biodegradable, hanging flushable ... H.E.B., a large supermarket chain headquartered in San Antonio, Texas, operates more ...
(Date:4/28/2017)... ... 28, 2017 , ... An April 24th article on Yahoo! Beauty discusses the case ... help of a weight loss surgery. The woman, declaring “I will not hate my body ... following her dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers ...
(Date:4/28/2017)... , ... April 28, 2017 , ... It's not always ... a number of illnesses that are unclear as to whether or not they are ... Bronchitis is one of these illnesses. So, FindaTopDoc took a look into the matter. ...
(Date:4/28/2017)... ... 2017 , ... Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ) announced ... its outlook as “stable.” At the same time, the ratings agency cautioned that the ... dip below “capital adequacy” thresholds required for its strong rating. , “Horizon is committed ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” ... Water, Global Climate Change and Your Health on Voice America sponsored by Nature’s ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... Calif. , April 19, 2017  IRIDEX Corporation ... will release financial results for the first quarter 2017 ... 2017.  The Company,s management team will host a corresponding ... p.m. ET. Investors interested in listening to ... 707-0665 for domestic callers or (703) 326-3030 for international ...
(Date:4/19/2017)... NEW YORK , April 19, 2017 /PRNewswire/ ... This report on the prostate cancer ... of the global market. Increasing prevalence of prostate ... as innovation in the development of new drugs ... hormone-refractory prostate cancer drug due to lesser side ...
(Date:4/19/2017)... India , April 19, 2017 ... and Application, Forecast to 2022 report has covered and analysed ... statistics and information on market size, shares and growth factors. ... major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and Figures, ...
Breaking Medicine Technology: